908 organization(s) found
Clubster NSL
Nutrition, health and longevity cluster of the Hauts-de-France region.
CML Advocates Network
CML Advocates Network (CMLAN) is an international organization that connects 131 patient organizations, across the globe in 96 countries. Initially founded by four CML patient leaders from Germany, Israel, the Czech Republic and the UK, it is led by a Steering Committee comprised of nine patient advocates representing all six world regions.
CNIO (Spanish National Cancer Research Centre)
Spanish national cancer research centre.
COBUCAN (Coalition Burkinabè Contre le Cancer)
The COBUCAN regroups 18 cancer civil society organisations with the overarching goal to strenghten national actions to prevent and control cancer in Burkina Faso. The objectives of the COBUCAN include: promoting the right to access cancer services; fighting stigmatisation related to cancer; improving quality of life of cancer patients; influence national cancer control policies; Capitalising on and sharing best practises, lessons learnt and other learning from cancer research; Supporting cancer control initiatives led by public and private actors; Ensuring collaboration with cancer associations in other countries and internationally; implementing awareness raising activities as well as training; organising with public authorities public events contributing to cancer control nationally and globally; potentially creating and supporting and managing centers and activities; participating with the Ministry of health to the implementation of cancer screening activities.
COG (Children's Oncology Group)
Clinical trials group dedicated to childhood and adolescent cancer, including pediatric leukemia.
Cold Spring Harbor Laboratory
Private non-profit research institution with a cancer centre and leukemia research teams.
Conac (Corporación Nacional del Cáncer)
In Spanish: "CONAC es una entidad de derecho privado sin fines de lucro destinada a servir a la comunidad a través de la educación, prevención, diagnóstico precoz, investigación y tratamiento de cáncer en nuestro país. Con presencia en 30 filiales del país de Arica a Punta Arenas, proporciona servicios con recursos propios en las siguientes áreas: 1. Apoyo Asistencial; 2. Apoyo Institucional; 3. Detección Precoz; 4. Educación y Capacitación; y 5. Prevención."
Concarlo Therapeutics
Concarlo's vision is to create a world of possibility, hope and time by making cancer a treatable, manageable and survivable condition. Concarlo's mission is to dramatically improve outcomes for patients with drug-resistant cancers by creating transformative therapies that control the p27 target.
Conile
In Spanish: "La corporación del niño leucémico CONILE busca brindar apoyo durante las diferentes etapas de la enfermedad a niños de escasos recursos y/o en situación de vulnerabilidad de la región de la Araucanía que presenten Leucemia u otro tipo de cáncer, cubriendo de forma gratuita medicamentos y exámenes de alto costo que no se encuentren insertos en el programa GES (Garantías Explícitas en Salud). Nuestra Misión: Brindar apoyo a niños, niñas y adolescentes con Leucemia y otras tipo de Cáncer, permitiendo mejorar su calidad de vida. Nuestra Visión: Ser un referente nacional e internacional al servir como ejemplo para otras instituciones en la ayuda a niños y familias en la lucha contra el Cáncer."
CRCL (Centre de Recherche en Cancérologie de Lyon)
Cancer research centre in Lyon.
CRCM (Cancer Research Center of Marseille)
A pioneer in cancer research, the Cancer Research Center of Marseille (CRCM) has been working for over 50 years to better understand the major biological mechanisms behind the disease and translate them into medical innovations. The CRCM stands out for its integrative approach - combining fundamental, translational and clinical research - in close collaboration with the Paoli-Calmettes Institute, the regional cancer center. This synergy, which brings laboratory research closer to clinical applications, makes CRCM a major player in the understanding and treatment of cancer.
CRCT (Centre de Recherches en Cancérologie de Toulouse)
Cancer research centre in Toulouse, located on the Oncopole campus.
CRISPR Therapeutics
Gene editing company with programmes in blood diseases and allogeneic CAR-T.
CROBIOBIO
In Spanish: "Con 30 años de servicio, apoyamos en sus terapias oncológicas a un gran número de personas de las regiones del Bío bío y Ñuble, ofreciendo servicios de acompañamiento espiritual y psicológico, alimentación basada en la evidencia científica, transporte hacia los centros de tratamiento y además un lugar cómodo y seguro donde poder descansar. MISIÓN: Institución de derecho privado, sin fines de lucro, laica y de orientación cristiana. Liderada por la presidenta de un directorio de socias voluntarias, con el propósito de acoger con respeto a la dignidad humana, cariño y alegría a los pacientes derivados del HRGGB u otras instituciones públicas o privadas de la Región del Bío Bío. Estos pacientes se hospedan en el Hogar Los Boldos de Concepción, por el período que dure su terapia oncológica. Se les proporciona los servicios de hospedaje, alimentación y traslado, además de variadas actividades de recreación, esparcimiento y apoyo espiritual. VISIÓN: CROBIOBIO es la institución que entrega las mejores condiciones de hospedaje, alimentación, traslado y acompañamiento a los pacientes de la Región del Bío Bío que acuden a sus terapias oncológicas en los distintos centros clínicos de la ciudad de Concepción y Talcahuano.
Crossbow Therapeutics
Crossbow Therapeutics is determined to improve the lives of people with cancer by unlocking the therapeutic potential of T-cell receptor (TCR)-mimetic antibodies. The company’s T-Bolt™ therapies are next-generation, easily assembled immunotherapies directed with high precision at previously unreachable cancer cell targets. Crossbow’s efficient and selective approach is designed to target the entire universe of cancer proteins, thus expanding the potential of antibodies therapy across cancers.
CRUK
We�re the world�s leading cancer charity, dedicated to saving and improving lives with our research.
CSCO (Chinese Society of Clinical Oncology)
The Chinese Society of Clinical Oncology (CSCO) founded in 2015, is a non-profit professional academic group voluntarily formed by clinical oncologists, related enterprises and institutions. CSCO has long been committed to carrying out Continuing Medical Education and multi-center collaborative research in clinical oncology, promoting the standardization of tumor diagnosis and treatment, and improving the academic level of clinical oncology in China. At present, CSCO has more than 30,000 individual members and nearly 200 group members or strategic partners, of which individual members are from national and some international practitioners or nurses engaged in clinical oncology diagnosis and treatment, and group members include international and domestic famous enterprises and professional media.
Cure Leukaemia
UK charity that funds a national network of blood cancer clinical trial centres.
Curenetics
Curenetics is an AI driven precision oncology company transforming how cancer treatments are discovered, developed, and selected. Our Cure-IO platform aggregates and analyses complex patient data including genomics, medical imaging, and clinical records from hospitals and laboratories to build advanced AI models that integrate multiple biomarkers. This multimodal approach delivers unprecedented predictive accuracy, helping identify those patients most likely to benefit from specific therapies.
CYBERNA
Cyberna is developing innovative in vitro diagnostic (IVD) tests for early detection of cancer through a simple blood drop
Cyrus Therapeutics
Cyrus Therapeutics is a leading biotechnology company that is discovering and developing innovative medicines to conquer chronic or life-threatening diseases with high unmet needs. It is estimated that about 3,000 targets are �undruggable� (about 16% of a total of 20,000 human proteins). We are committed to making our mission��drugging the undruggable targets��possible with small molecule drugs as well as new chemical modalities such as targeted protein degraders.